Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Nov 1;88(3):234-237.
doi: 10.1097/QAI.0000000000002787.

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Arturo Ciccullo  1   2 , Vanni Borghi  3 , Andrea Giacomelli  4 , Maria Vittoria Cossu  5 , Gaetana Sterrantino  6 , Alessandra Latini  7 , Andrea Giacometti  8 , Andrea De Vito  9 , William Gennari  10 , Giordano Madeddu  9 , Amedeo Capetti  5 , Gabriella d'Ettorre  11 , Cristina Mussini  3 , Stefano Rusconi  4 , Simona Di Giambenedetto  2   12 , Gianmaria Baldin  12   13
Affiliations
Free article
Multicenter Study

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Arturo Ciccullo et al. J Acquir Immune Defic Syndr. .
Free article

Abstract

Background: Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1-positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort.

Methods: This was a retrospective study enrolling HIV-1-infected, virologically suppressed patients switching to dolutegravir + lamivudine. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1000 copies/mL or by 2 consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (defined as the interruption of either 3TC or dolutegravir), assessing predictors via Cox regression analyses.

Results: Seven-hundred eighty-five patients were considered for the analysis: 554 were men (70.6%), with a median age of 52 years (interquartile range 45-58 years). Estimated probabilities of maintaining virological suppression at weeks 96, 144, and 240 were 97.7% (SD ±0.6), 96.9% (SD ±0.8), and 96.4% (SD ±0.9), respectively. A non-B HIV subtype (P = 0.014) and a previous VF (P = 0.037) resulted predictors of VF. We did not observe differences in probability of VF in people living with HIV with an M184V resistance mutation (P = 0.689); however, in a deeper analysis, M184V mutation was a predictor of VF (P = 0.038) in patients with time of virological suppression <88 months. Estimated probabilities of remaining on study regimen at 96, 144, and 240 weeks were 82.9% (SD ±1.4), 79.7% (SD ±1.6) and 74.3% (SD ±2.2), respectively.

Conclusions: Our findings show the long-term efficacy and tolerability of dolutegravir plus lamivudine in virologically suppressed patients.

PubMed Disclaimer

Conflict of interest statement

A. Ciccullo received travel grants from ViiV Healthcare. A.G. reports grants and/or personal fees from BMS, Gliead, Janssen, MSD and ViiV Healthcare. A. Capetti has received a personal grant from AB, Gilead, and ViiV. G.S. has received funds for speaking by Gilead, Merck, Janssen, AbbVie, and ViiV. C.M. has participated in advisory boards and received study grants and/or speaker honoraria from AbbVie, Gilead, ViiV, Janssen, Angelini, BMS, and MSD. S.R. received research grants to his institution from ViiV Heathcare, Gilead Sciences, and Janssen, outside the submitted work; he was also a paid consultant for ViiV Heathcare, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, and Janssen. S.D.G. was a paid consultant or member of advisory boards for Gilead, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme, and Bristol-Myers Squibb. The remainig authors have no conflicts of interest to disclose.

References

    1. European AIDS Clinical Society. EACS Guidelines for the Management of People Living with HIV (PLWH) in Europe. Version 10.1. Available at: https://www.eacsociety.org/files/guidelines-10.1_5.pdf . Accessed November 21, 2020.
    1. Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018;19:713–738.
    1. Fabbiani M, Gagliardini R, Ciccarelli N, et al.; ATLAS-M Study Group. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018;73:1955–1964.
    1. Pulido F, Ribera E, Lagarde M, et al.; DUAL-GESIDA-8014-RIS-EST45 Study Group. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral Suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis. 2017;65:2112–2118.
    1. Arribas JR, Girard PM, Landman R, et al.; OLE/RIS-EST13 Study Group. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:785–92. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.

Publication types